Conference Reports for NATAP

Back

The International Liver Congress™ EASL - European Association for the Study of the Liver Paris France 11-15 April 2018     Summary from EASL 2018 for Hepatitis C (HCV) HCV in 2018: Success stories and remaining challenges? - Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany- (05/04/18)   -----------------------------------------------   RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients - (06/12/19)   A first-in-class orally available HBV cccDNAdestabilizer ccc_R08 achieved sustainable HBsAg and cccDNA reduction in the HBVcircle mouse model - (06/12/19)   Antigen suppression effect of the core protein allosteric modulator RO7049389 in AAV-HBV mice is accompanied by transient upregulation of immune-cell gene signatures in the liver - (06/12/19)   Hepatitis C (HCV) patients with HIV co-infection demonstrate unique liver-related complications and health behaviors compared to HCV mono-infected patients - (07/03/18)   Field evaluation of Xpert (Cepheid) Hepatitis C Virus assay for RNA quantification in Genotype 6 predominant patient population in Cambodia - (06/07/18)   Evaluation of the Xpert fingerstick HCV viral load assay - (06/07/18)   The Rapid-EC Study - a Feasibility Study of Point-Of-Care Testing in Community Clinics Targeted to People Who Inject Drugs in Melbourne, Australia - (06/07/18)   One-Step Diagnostic Strategy of Viraemic Hepatitis C Virus infection From Dried-Blood Spots: feasibility and usefulness in people who inject drugs - (06/07/18)   The Association of Circulating MicroRNAs (miRs) With Liver Fibrosis Stage and the Impact of Selonsertib Treatment in Patients With NASH - (05/23/18)   BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis: A Population Pharmacokinetics and Exposure-Response Analysis - (05/22/18)   BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue, Reduces Fibrosis and PRO-C3 in a Mouse Model of Non-Alcoholic Steatohepatitis - (05/22/18)   Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a - (05/21/18)   Establishment of persistent functional remission of HBV and HDV infection following REP 2139-Ca and pegylated interferon alpha-2a therapy in patients with chronic HBV / HDV co-infection: 1.5 -2 year follow-up results from the REP 301-LTF study - (05/21/18)   Evaluation of SOMAscan® as a Discovery Platform to Identify Noninvasive Protein Biomarkers for Diagnosis and Monitoring of NASH - (05/21/18)   The Association of Circulating MicroRNAs (miRs) With Liver Fibrosis Stage and the Impact of Selonsertib Treatment in Patients With NASH - (05/21/18)   Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a - (05/18/18)   ACC Inhibitor Demonstrates Potent Antifibrotic Activity In Vitro and In Vivo - (05/17/18)   Responsiveness of Controlled Attenuation Parameter and Its Correlation With Magnetic Resonance Imaging-Proton Density Fat Fraction in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (05/15/18)   Combination of an FXR Agonist and an ACC Inhibitor Increases Antifibrotic Efficacy in Rodent Models of NASH - (05/15/18)   Preliminary Efficacy and Safety of Acetyl-CoA Carboxylase Inhibitor GS-0976 in Patients With Compensated Cirrhosis Due To NASH - (05/15/18)   Accurate Prediction of Clinical Disease Progression in Patients With Advanced Fibrosis Due to NASH Using a Bayesian Machine Learning Approach - (05/15/18)   The Conundrum of Cryptogenic Liver Disease [NASH] with Advanced Fibrosis: Poor Clinical Outcomes without Treatment Options - (05/15/18)   Novel Characterization of the Gut Microbiome in Patients With NASH and Longitudinal Changes Associated With Histologic Improvement - (05/15/18)   Mechanism for Hypertriglyceridemia and Effect of Fibrate Coadministration During Acetyl-CoA Carboxylase Inhibitor Treatment - (05/11/18)   Characterization of Changes in Lipoprotein Profiles of Patients With Nonalcoholic Steatohepatitis Treated With the Acetyl-CoA Carboxylase Inhibitor GS-0976 - (05/09/18)   Evaluation of Renal and Bone Safety in Post-Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis - (05/08/18)   MINIMAL MONITORING OF DIRECT-ACTING ANTIVIRAL THERAPY WITHIN A REAL WORLD, URBAN.......Adherence to provider visits/Adherence to prescriptions - (05/08/18)   Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Adolescents With Chronic Hepatitis C Virus Infection and Hematologic Malignancies Undergoing Chemotherapy - (05/08/18)   Has increased rollout of direct acting antiviral therapy decreased the burden of late presentation and advanced liver disease in patients starting Hepatitis C Virus therapy in Germany? - (05/04/18)   The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while their survival after transplantation is improving: A study based on European Liver Transplant Registry - (05/04/18)   Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial - (05/01/18)   Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of MyrcludexB in combination with Tenofovirin patients with HBV/HDV coinfection - (05/01/18)   RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAgpositive and negative patients with chronic HBV - (04/30/18)   Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection - (04/30/18)   Effects of Inarigivir (SB9200) Therapy on Immune Responses in Patients with Chronic Hepatitis B (CHB) - (04/30/18)   Preclinical antiviral drug combination studies utilizing novel orally bioavailable agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, an HBV RNA destabilizer - (04/30/18)   Durable inhibition of hepatitis B virusreplication and antigenemia using subcutaneously administered siRNA agentAB-729 in preclinical models - (04/30/18)   An Integrated Safety Analysis of Phase 2 Studies of BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis - (04/25/18)   Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study - (04/25/18)   Marked reduction in prevalence of hepatitis C viremia among people who inject drugs (PWID) during 2nd year of the Treatment as Prevention (TraPHepC) program in Iceland - (04/24/18)   Hepatitis C Care Cascade in the Country of Georgia After 3 years of Starting National Hepatitis C Elimination Program - (04/24/18)   Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia - (04/24/18)   Low-moderate alcohol use is associated with a lower prevalence of non-alcoholic fatty liver disease in Hispanics/Latinos living in the US: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) - (04/24/18)   Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI - (04/24/18)   Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study - (04/24/18)   Marked reduction in prevalence of hepatitis C viremia among people who inject drugs (PWID) during 2nd year of the Treatment as Prevention (TraPHepC) program in Iceland - (04/23/18)   HCV Testing and Linkage to Care: Expanding Access to HCV Care Through Electronic Health Engagement - (04/23/18)   Substantial comorbidities and rising economic burden in real-world non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC): A large German claims database study - (04/23/18)   Early versus Delayed Hepatitis C Treatment Provides Increased Health Benefits at Lower Costs: A Pan-Genotypic Cost-Effectiveness Analysis Set in Scotland - (04/23/18)   Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks - (04/23/18)   Role Of Physician Specialties To Close Gaps in the Care Cascade of Hepatitis C: Evidence From Paid Claims in the United States From 2010 To 2016 - (04/23/18)   Post-treatment liver stiffness measurement is not useful to predict hepatocellular carcinoma in HCV patients who achieve SVR - (04/23/18)   Safety And Efficacy At 1 Year After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide In Chronic HBV Patients With Risk Factors For TDF Use - (04/23/18)   Novel and Potent HBV Capsid Modulator Reduces HBeAg and cccDNA in Core-site Directed T109I Mutant in HepNTCP Cells - (04/20/18)   Clinical and virological characteristics of DAA-experienced patients with chronic HCV infection treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX): results from the Frankfurt Resistance Database - (04/20/18)   DIRECT-ACTING ANTIVIRAL TREATMENT IN SUB-SAHARAN AFRICA: A PROSPECTIVE TRIAL OF LEDIPASVIR/SOFOSBUVIRFOR CHRONIC HEPATITIS C INFECTION IN RWANDA (THE SHAREDSTUDY) - (04/20/18)   Collocation of Buprenorphine with HCV Treatment to Improve Adherence and Reduce Harm in PWID with HCV Preliminary Data from the ANCHOR STUDY - (04/20/18)   HepFree: Screening migrant patients for viral hepatitis in primary care. A 90,000 patient randomised controlled trial indicates benefits are most obvious in older patients/UK-London - (04/20/18)   Glomerular filtration rate changes after treatment of chronic hepatitis C patients with direct-acting antivirals: an observational study - (04/20/18)   Spontaneous Clearance of HCV RNA after Documented Relapse following DAA-therapyA case-control study - (04/20/18)   Efficacy and Safety of Elbasvir/Grazoprevir in Women Infected With Hepatitis C Virus Genotypes 1 or 4 and Coadministered Oral Contraceptives or Hormone Replacement Therapy - (04/20/18)   Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral therapies targeting patients with advanced liver fibrosis - (04/20/18)   DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic HBV Infection, with Improvement During Treatment - (04/20/18)   NGM282 Significantly Improves Markers of Bile Acid Synthesis, Hepatic Injury and Fibrosis in PSC Patients: Results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial - (04/20/18)   NAFLD and risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma in four European primary care databases - (04/19/18)   The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) - (04/19/18)   NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients With Biopsy-Confirmed NASH, Which is Preceded By Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis Markers at 6 Weeks - (04/19/18)   A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH) - (04/19/18)   MGL-3196, a selective thyroid hormone receptor-beta agonist, significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study - (04/19/18)   Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2b CENTAUR Study - (04/19/18)   Proof-of-concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor (FXR) agonist (GS-9674) in NASH - (04/18/18)   Interim Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM), in Healthy Volunteers and Non-Cirrhotic Viremic Subjects with Chronic Hepatitis B - (04/18/18)   RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated - (04/18/18)   Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAgloss in an AAV-HBV mouse model - (04/18/18)   Safety, Pharmacokinetics and Antiviral Activity of Novel HBV Capsid Assembly Modulator, JNJ-56136379, in Non-cirrhotic, Treatment-naïve Patients with Chronic Hepatitis B - (04/18/18)   NAFLD and risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma in four European primary care databases - (04/18/18)   Efficacy and Safety of Elbasvir/Grazoprevir in Women Infected With Hepatitis C Virus Genotypes 1 or 4 and Coadministered Oral Contraceptives or Hormone Replacement Therapy - (04/17/18)   NS5A resistance patterns and treatment outcomes in DAA-naïve genotype 1a (GT1a) chronic hepatitis C patients with and without baseline resistance-associated substitutions (RASs) - (04/17/18)   DISEASE OUTCOMES AFTER DAA-INDUCED SVR: DATA FROM THE RESIST-HCV COHORT - (04/17/18)   SVR IS THE STRONGEST PREDICTOR OF OCCURRENCE AND RECURRENCE OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS AFTER TREATMENT WITH DIRECT ACTING ANTIVIRALS: A PROSPECTIVE MULTICENTER ITALIAN STUDY. - (04/17/18)   Effectiveness Of Hepatitis C Virus Screening Laws in the United States: Evidence From Paid Claims Data From 2010 To 2016 - (04/17/18)   Testing and linkage to care outcomes in baby boomers verses young adults tested in the community and linked to care at a Federally Qualified Health Center in the US - (04/17/18)   UTILIZATION OF ELBASVIR / GRAZOPREVIR (EBR/GZR) AND ADOPTION OF RESISTANCE ASSOCIATED SUBSTITUTIONS (RAS) TESTING IN REAL-WORLD TREATMENT OF HCV GENOTYPE 1 (GT1) INFECTION: RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (04/17/18)   Z-PROFILE: Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada - (04/17/18)   Impact of Acid-Reducing Agents on Effectiveness of Elbasvir/Grazoprevir in Treating US Veterans Affairs Population with Hepatitis C Virus - (04/17/18)   Incidence and Prevalence of Extrahepatic Manifestations of HCV - (04/17/18)   C-EDGE Treatment Experienced: Effect of 12-Week Oral Regimens of Elbasvir and Grazoprevir on Health Related Quality of Life in Prior Treatment Experienced Patients With Chronic Hepatitis C Infection - (04/17/18)   Hepatic Safety and Biomarker Assessments in Sorafenib-experienced Patients With Advanced Hepatocellular Carcinoma Treated With Nivolumab in the CheckMate-040 Study - (04/16/18)   IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multicenter prospective trial in Italy - (04/16/18)   Long-term impact of HCV eradication after all oral therapy in patients with clinical significant portal hypertension - (04/16/18)   No evidence of fibrosis regression in HCV/HIV co-infected and HCV mono-infected participants up to 3 years after achieving SVR with DAA treatment: interim results from the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) - (04/16/18)   Survival Benefits of Direct-Acting Antiviral Therapy in Patients with Decompensated Hepatitis C Cirrhosis - (04/16/18)   Survival Benefits of Direct-Acting Antiviral Therapy in Patients with Decompensated Hepatitis C Cirrhosis - (04/16/18)   Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir Among 723 Patients with Chronic Hepatitis C: The NAVIGATOR-II Study - Interim Analysis - (04/16/18)   Risk of Total Non-hepatic Cancer Following Treatment for HCV Infection with Direct-acting Antiviral Agents - (04/16/18)   Long-Term Follow-up of Patients with Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment with Sofosbuvir-Based Regimens - (04/16/18)   Scaling up HCV-DAA treatment in patients on opioid substitution therapy - does alcohol or cannabis consumption diminish cure rates? Data from the German Hepatitis C Registry (DHC-R) - (04/16/18)   Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy - (04/16/18)   Treatment of non-cirrhotic HCV genotype 4 infected patients with 8 weeks of ledipasvir/sofosbuvir: an open-label, multicenter clinical trial - (04/16/18)   NGM282 Significantly Improves Markers of Bile Acid Synthesis, Hepatic Injury and Fibrosis in PSC Patients: Results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial - (04/16/18)   HCC RECURRENCE UNDER ALL-ORAL DAAs-BASED ANTIVIRAL THERAPY IN HCV-INFECTED PATIENTS: DATA FROM THE NAVIGATORE WEB PLATFORM - (04/16/18)   A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non-severe fibrosis : STREAGER - (04/16/18)   Hepatic Safety and Biomarker Assessments in Sorafenib-experienced Patients With Advanced Hepatocellular Carcinoma Treated With Nivolumab in the CheckMate-040 Study - (04/13/18)   8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort - (04/13/18)   FIRST REAL-WORLD DATA ON SAFETY AND EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: DATA FROM THE GERMAN HEPATITIS C-REGISTRY - (04/13/18)   EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: THE ENDURANCE-5, 6 STUDY - (04/13/18)   Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network - (04/13/18)   Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network - (04/13/18)   Safety and Efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in Genotype 3 HCV-Infected Patients with Cirrhosis - (04/13/18)   Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Psychiatric Disorders - (04/13/18)   Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Patients With Chronic HCV Genotype 1-6 Infection - (04/12/18)   Direct Acting Antiviral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Real World Experience from the HCV-TARGET Cohort - (04/12/18)   Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naive participants - (04/12/18)   RETREATMENT OF HEPATITIS C VIRUS INFECTION IN PATIENTS WHO FAILED GLECAPREVIR/PIBRENTASVIR - (04/12/18)   Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the TRIO Network - (04/12/18)   Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Infection and Prior Treatment Experience: An Integrated Phase II/III Analysis - (04/12/18)   HCV Micro-Elimination Funding Grants Available - (04/12/18)